Is Cancer a Parasite? A Radical New Perspective with William F. Supple PhD

SHOW NOTES

📧 Email Address

• billsupple24@gmail.com

📗𝗕𝗼𝗼𝗸

• Cancer is a Parasite
• The Sunlight Solution (upcoming June)

He shares research and case studies via his Substack:
🔗 https://fenbendazole.substack.com

 00:00 – Introduction to cancer and current models
03:30 – Guest introduction & background
05:00 – Personal story: mother-in-law case
10:00 – Fenbendazole discovery & early results
15:00 – Scientific background and credibility
16:30 – Cancer as a parasite theory explained
25:00 – Mechanisms: microtubules & cell destruction
30:00 – Multiple pathways of antiparasitic action
35:00 – Historical research & suppression claims
40:00 – Evidence and controversy in medicine
45:00 – Doctors, risks, and adoption barriers
47:00 – Global parasite treatment vs cancer rates
53:00 – Prevention insights and public health
54:30 – Practical advice and dosage discussion
59:00 – Closing thoughts and summary

Is Cancer a Parasite? A Radical New Perspective with William F. Supple PhD

Dr Ron Ehrlich (00:05)

Hello and welcome to Unstress Health. My name is Dr. Ron Ehrlich.

Well, today we explore the subject of cancer, but from a very, very unique perspective. Now cancer affects something like 500 million people globally, about 10 million people a year die from cancer. It’s very unlikely that anyone listening to this doesn’t know someone within one degree of separation from themselves, if not themselves who hasn’t had it.

So cancer is a huge and growing problem and literally billions of dollars have been spent looking for the magic bullet, looking for the cure for cancer. And so much of the attention in cancer research has been around cancer as a mutation of gene production of genes in general. And I would have to say if the evidence is anything to go by and so much.

All of this research has been focused on that model, that something is seriously wrong if we are indeed practicing evidence-based medicine. Well, my guest today challenges that. My guest is William Supple Jr. Now William has got a PhD in neuroscience, so he has certainly understands the science and arguably because he is not directly involved in cancer research.

He may well approach this or he has, as you will hear, approach this from a very open minded perspective, driven by his own personal experience, which is often the way that medical practitioners or people in general have an epiphany. He’s the author of a book called Cancer is a Parasite. And he’s also the author of another book coming up in June called the Sunlight Solution. 

And we’ll definitely be getting him back for that, but in his work, Bill explores provocative ideas about cancer biology and repurpose drugs, medications, and the role of chronic of vitamin D in chronic disease. So today we examine the science behind his hypothesis about cancer as a parasite. Now, I must admit when I first got suggested to talk to William, I did it pick my interest as to what he actually meant by that.

And he defines that very carefully and comes up with some truly a-ha shocking moments and very empowering moments too. And here we are again, talking about repurposed drugs. Now to any regular listener of this podcast, you will know that the two words business model seem to go a long way to explain how our world works in general and how our health system works in particular. It’s a great business model, just not a very good health model.

And repurpose drugs have very little appeal to researchers and public health authorities, ironically, because, well, guess what? Some of them are a little bit too effective and that’s not good for the business model. Well, today we explore one of those drugs and I think you will be truly shocked and surprised and I hope empowered by what we cover here today. I hope you enjoy this conversation I have with William Supple.

Welcome to the show, Bill.

William F. Supple PhD (03:31)

Thanks Ron, great to be here.

Dr Ron Ehrlich (03:33)

Now, Bill, you’ve written a very interesting book with a very compelling title, Cancer is a Parasite, and you offer a very different framework of an understanding of, of cancer. So what, what initially made you question that traditional genetic mutation model of cancer?

William F. Supple PhD (03:54)

Well, mean, first off, I’m here with good news today. There appear to be legitimate cures for a number of different types of cancer in the form of antiparasitic drugs. And my book is about Phenbendazole in particular. So I got into this kind of as a happy accident. So my mother-in-law was diagnosed with metastatic breast cancer back in 2021. And she, at the time, she was 83 and had, you know, went in for a bowel obstruction and they did some imaging and found that she basically had cancer everywhere. Lungs, liver, bones, kidneys, basically too many places to count.

And at 83, she had decided she didn’t want to go through chemotherapy. So she went, was released home to hospice. I mean, she was so bad that she actually received last rights in the hospital because she wasn’t sure she would make the trip home, which was about five miles. So she was that bad. ironically, the morning after we got that news, I was just going through what I typically read.

And I just happened to be looking at an article on vitamin D of all things. I was reading a specific article about how bacteria causes stomach cancer. And in the comments, there was a comment that said, look at fendendazole, it cured my prostate cancer. And that started to where we are today that kind of lit a match to an interest. So I started to look at the research and I found a few case reports, but the preclinical research on fendendazole was pretty compelling that it’s worth a shot, especially for someone who’s not going to do anything else. 

So I went down to, you know, it’s over the counter. It’s an animal anti-parasitic drug. I went down to in the states in Vermont, we have what’s known as tractor supply and it’s basically an animal feed type store. So I went down and got a package of it and I tried it myself. It didn’t kill me. And I sent a pack to my, it’s about, you know, $8. So I sent a pack to my wife who was with her mother down in Florida and she tried it. We figured 50 % genetic match. You know, we didn’t want to make a sick person sicker. 

So my wife took it. No reaction. So we, presented the idea that maybe my mother-in-law should try fennbendazole to see what happens. She had nothing to lose and it was basically a Hail Mary. Well, her husband, we got a bunch of it on Amazon. You know, for about $50, you can get about six months supply. So we bought it on Amazon and he started mixing it in her daily yogurt. You know, she was kind of out of it. 

Whether she realized she was getting it or not, you know All the kids agreed that she should do it and you know her husband and she did as well so in about two to three weeks she started to perk up and her appearance activity appetite all greatly rebounded from where she was which was basically moribund and she Felt well enough to dismiss hospice and after about a month, she felt well enough to go back to the oncologist who had dismissed her, given up on her for dead. So she was surprised. He was surprised to see her. So they did some testing in her blood tumor marker for breast cancer, which is CA 2729, went from 316 down to 131. So we knew something was happening. The only thing she had gotten was vanvendazole.

So, you know, obviously he was amazed and he said, continue to do what you’re doing. So she continued to do what she was doing. And after about six months, her blood tumor markers were normal. She was up and around, you know, she started riding her bike at three to four months. And, know, she’s getting ready to celebrate her 88th birthday. So if I didn’t actually see that, I wouldn’t have believed it. It was just a remarkable turnaround.

Not one single side effect. So it was as if, you know, it was a true miracle happening right in front of us. So she, she kind of became an urban legend and in her little town. So everyone wanted to know how did she do it? You know, how come she’s still here? How did she survive metastatic breast cancer? 

So, you know, it’s like anything word of mouth travels fast and we my wife and I would tell people what happened, but you end up telling the same story. Dozens of times it gets tedious. So we determined that we should have some sort of a vehicle to get her story out there. So what I did is I started a sub stack, which is a online publication here in the States that has a lot of alternative medical stuff in it. So it’s actually a nice service. 

So I started that sub stack called bend, bend is all dot sub stack.com. And I did it under the pseudonym Ben fan because I’m not an oncologist and I’m not an MD, I’m a PhD. And I felt that the, the message was what mattered, not the messenger. So I did it anonymously. So, so I published her case report so I had all her information and it was about a year out from her initial diagnosis and she was happy as a clam. 

I published that and then what started to happen were simultaneously other people were both motivated to try to self-treat their own cancers or were currently self-treating with fendt-bendazole and they said it worked for me too. So it kind of became this online gathering place where people who were self-treating with fendendazole could tell their story. So I did that for a couple of years and was publishing detailed case reports as best that we could. People would tell us, give us information.

Again, as best they could, they just come through a hellish experience and they weren’t necessarily trying to record all the information for publication, but they had pretty good records. the common feature, the power in the case reports was that everybody did something different. The control was the lack of control.

It was so haphazard that the only thing that was common in all the case reports, you’ll see them in the book, was the presence or absence of fendendazole. So it didn’t really matter what type of solid tumor cancer they had. It didn’t really matter how much they took as long as they were sure that they had absorbed it. And it didn’t really matter how often they took it.

So it’s a really interesting product where it seems to be like a primary poison for cancer cells. the interesting thing is that, again, it’s an anti-parasitic used for animals primarily. But there are analogs in humans as well that are basically the same drug, but it’s approved for humans human use so it’s going to be a lot more expensive obviously but the pharmacological scaffold is the same. So whether you use my bendazole, albendazole, fenben, oxy, fendazole, thibendazole, it’s all kind of the same stuff. So I forget where I was going with that.

Dr Ron Ehrlich (12:59)

Well, well, well, hang on there, Bill, because where you are got up to is quite extraordinary. There’s so much here to unpack about, a cheap, repurposed drug. mean, the alarm bells are going off in the cancer industry right there, because we hear so many breakthroughs of wonderful new drugs that are phenomenally expensive. 

And yet we still have an epidemic of you know, of cancers  it’s interesting because so much disease, are two schools that I’ve been aware of, and you’ve introduced another one, the mutation model of gene mutation. And that’s been the focus of literally billions of dollars worth of research and literally billions or trillions of dollars worth of sales. The fact that cancer is a genetic mutation model of cancer. That’s one thing.

I think a lot of people look at cancer as a metabolic disease and an energy thing. Um, but here you are introducing a different model. What do you think? And do your background will come? Well, actually it might be interesting to just get a little bit of your background there first, uh, in terms of you’ve got a PhD. Tell us a little bit about your background.

William F. Supple PhD (14:24)

Right. So I’m trained as a neuroscientist. So I graduated from Dartmouth in 1986 and I, I studied brainstem mechanisms of behavior, broadly defined specifically learning and memory. Right. So I used, you know, I used, you know, various neuroanatomical behavioral and electrophysiological methods to basically record how neurons learned and remembered things in living, behaving animals. 

So that’s my background is systems neurobiology, looking for where the stuff of learning and memory is stored and how that might be expressed in behavior. So I actually found one of the N-grams in 1986 and we published a paper in Science that found the N-gram for what’s known as long-term habituation in the midline cerebellar vermis. So that was kind of my claim to fame way back then.

Dr Ron Ehrlich (15:41)

But I guess, I guess the point about, I guess the point in just giving us that little bit of background is you’ve got a PhD in neuroscience. So you will have a fair grasp of, I think this is an understatement and I say it with all due respect, you’ve got a good grasp of, of science and the scientific model. 

And yet, and yes, perhaps one could argue that not being an oncologist, not being locked into the gene mutation model, not being connected with research or requiring a research funding. You approach this with an open professional mind. And, and now my next question to you is, cause you must have thought about this many times. What is, what do you think the biological mechanisms are that you’re proposing here? What’s going on?

William F. Supple PhD (16:36)

Well, one common misperception with the cancer is a parasite notion is that parasites cause cancer. That’s not what I’m saying. What I’m describing is the nature of cancer. What is cancer? And what I’m saying is cancer is parasite. It doesn’t speak to what causes cancer. Now, as you get deep into the book, we talk about, you know, untreated subthreshold parasitic infections that are rampant in the Western world that could be a, occult risk factor for cancer. But that those two ideas are totally separate. So what, the book is all about, later in the book. 

So the book starts out describing, how fendt-bendazole kills parasites.I talk about how Fendendazol uses the same mechanisms to kill cancer cells. you know, lucky us, cancer cells have the same structural weakness that parasites do. So, and then I talk about why are, why is this information not really well known? And that’s kind of an interesting side of the book. But as far as what causes cancer. I really don’t speak to that. The cancer as a parasite theory is just that, it’s a theory, it’s a way to think about it. 

And the way I came up with it was I was reading a bunch of articles about parasitology and cancer at the same time and I kept it over the months I would be deep into an article and I have to go back to the title to determine whether it’s reading about cancer or a parasite. And you do that 50 times, eventually the light bulb goes off that we’re talking about two things that are very similar. 

And the fact that an anti-parasitic drug is killing cancer cells. It’s not, you know, you don’t have to be Einstein to make the leap that cancer and parasites share all these different features, most notably you know, the elephant in the room is that an anti-parasitic drug. fendendazole is what I focused on because it’s over the counter and cheap and easy to find. And that’s what people are self-treating with. But there’s a lot of different anti-parasitic drugs that have anti-cancer capabilities. 

So it’s not just fendendazole. the basic clinical Petri dish, in vivo, animal stuff, all that research has been done. And, you know, a lot of the scientists who endeavor in that field have done all the heavy lifting. And what’s missing is the translation to human clinical trials. And this is where the politics come into it. There been a number of instances where, you know, this wheel keeps getting reinvented. To fend bend is all anti-parasitic, secure cancer wheel. And I’ll tell you about that in a minute, but it will, a scientist will discover what I discovered. You know, usually there’ll be an research institution and that has all the institutional capture and regulatory capture and professional risk that these people would entail, would endure if they were to say that publish a book like I did. 

Mean, I’m the only one who could have published this book because I have nothing to lose, which is I think what you’re getting at before. it’s kind of like, so, and I’m not really captured intellectually or by what I, by dogma, you know, to say for an oncologist to say that cancer is a parasite would be heresy. They’d be, you know, laughed. Left out of the the arena because it’s so obvious and because it’s so it’s a bold statement, but it’s true. 

And what happened was as I tried to, so the way scientists work is you do hypothesis testing, you try to prove that cancer isn’t a parasite, right? You would try to prove that statement to be wrong. Well, I couldn’t prove it wrong. And what I’m hoping is that when the book is out, the parasitologist, the bug people will hook up with the oncologists.

The cancer people and that they will realize that there’s a lot of synergy between their two fields. And the really exciting thing is if you’re using parasites as a model for cancer, you can accelerate the development of drugs on parasites. You don’t have to test it on humans. So you could have rapid drug development. 

You could see how the parasite is going to develop resistance to it. And you can anticipate all of these things and tweak your drug and make it more perfect before you ever test it on a human. the model is very powerful and some of the details in the book where cancer is a parasite so that we can, one thing I wanted to really make sure that I talked about today was if this is, why is it somebody like me discovering this and it’s really not me. This Phenbendazole and anti-parasitics appear to go through like a 20 year cycle where they’re discovered and then they disappear. It seems like they’ve been been suppressed. So as I go through, as I was going through my research.

I was about 95 % sure that Fenbendazole was the real deal because I had my mother-in-law who, you know, it cured her. It’s not like ⁓ in between response. No im- you know, blood tumor marker normal, no evidence of, no imaging evidence of cancer at all. Till today. So, breast cancer.

Dr Ron Ehrlich (23:24)

Can I just stop you because, mean, this is quite a remarkable discovery or connection, let’s put it that way, fraught with problems, fraught with problems, because if anybody in a research institute that studies cancer would come up with a cure for cancer that is worth a dollar or two, they will be pillar read, run out of research and we’ll never see the light of day again. And I think this is a story that is very easy for the public to miss. But once you become aware of it, difficult to ignore. I think your scientific background, which clearly you have in order your neuroscience and PhD background,  is, is clearly well placed to make connections. You mentioned that Pat, the, and I love the fact that you’re saying parasites don’t cause cancer and you’re not even sure, we’re not even talking about why that might even be the case. 

We’ve covered many reasons in environmental nutritional medicine. You know, the question is, why don’t we all have cancer given what we’re exposed to, not why did I get it? But I’m intrigued by your statement about the structural weaknesses, the similarities between a parasite and a cancer cell, because essentially a cancer cell in the breast is, is really instead of breast cells being there, there are cancer cells which don’t do the same work as a breast cells do. And similarly in a prostate and in lung and gut, you know, they’re, they’re, they’re rogue cells. What’s the structural weakness that I have in common.

William F. Supple PhD (25:09)

So the main, know, if it was a multiple choice test and you asked on the test, is the main similarity attacked by fanbendazole that cancer and parasite cells share? would be, it attacks the microtubules. So parasite and cancer microtubules share the same structural weakness where that Phenbendazole binds, highly, has a high affinity to bind to both parasite beta tubulin and ⁓ cancer beta tubulin. So they both share that same genetic weakness. But Phenbendazole, that’s main reason. So once you clog the microtubules, which is the skeleton and the transport system of the cell, it dies a number of different ways. It starves to death, it explodes.

You know, if a cancer cell has a problem, it will self-destruct through a process called apoptosis and through oncogenes, P53 being the main oncogene will be triggered to kill the cell or disabled so that a cancer cell remains active. the way that, so that’s just one mechanism that FenBEN uses to kill cancer cells and parasites, but it has 10 other ways. So some of them are, it’ll block glucose uptake, it’ll block angiogenesis, the development of new blood vessels.  

It’ll mess around with molecular mimicry so that the phembendazole prevents a cancer cell from cloaking itself in antigens that protect it from the immune system. Essentially, it becomes invisible. So, Phenbendazole destroys that. It also disrupts the tumor microenvironment, which a tumor is a heterogeneous group of cells. 

And what it does as it forms the tumor, it will create what’s known as a stroma, which is more or less like a force field of cells that keep material and it’s a protective coating that protects the cancer cells inside, especially important in pancreatic tumors. So, Phenbendazole blows that apart. It destroys the stroma.

Promotional (27:52)

Hi, Dr. Ron here, and I want to invite you to join our unstresshealth community. Now, like this podcast, it’s independent of industry and focuses on taking a holistic approach to human health and to the health of the planet. The two are inseparable. There are so many resources available with membership, including regular live Q and A’s on specific topics with special guests, including many with our amazing unstresshealth advisory panel.

We’ve done hundreds of podcasts, all worth listening to, with some amazing experts on a wide range of topics. Many are world leaders. But with membership, we have our Unstressed Lab podcast series, where we take the best of several guests and carefully curate specific topics for episodes which are jam-packed full of valuable insights.

So join the Unstress Health Community. If you’re watching this on our YouTube channel, on the link below. Or just visit unstresshealth.com to see what’s on offer and join now. I look forward to connecting with you.

William F. Supple PhD (29:04)

It also will disrupt the drug efflux pumps on the surface of the cell. So cancer cells and parasites have defense mechanisms to protect them from outside agents that might disrupt them. let’s say you infuse a toxic substance, a cancer drug or an anti-parasitic, next to a parasite cell or cancer cell or vice versa. It has a defense mechanism called drug efflux pump, P, glycoprotein pump, if you’re interested in that. 

Excuse me. the, the, instead of, so as the substance is being passively diffused into the cell, these pumps pump it out, kind of like a leaking boat with a bilge pump antiparasitics disrupt that process as well. So there’s a number of different ways that phenbendazole can kill the cancer cell. The reason why you have no side effects with phenbendazole is because the cancer cell or the parasite has a hundred times greater affinity for the drug than to do healthy cells. So you don’t get any side effects.

So, and the beauty of and bend is all is that it’s you take it by mouth. It goes through the circulatory system and binds like a magnet to the cancer cell, finds it and destroys it. And the reason why it’s so effective is it, like I said before, it doesn’t just kill the cell one way. Like if the cell is trying, if the cancer cell is mutating and it becomes less sensitive to the microtubule effect.

It’s got nine other ways that phenbenzoyl is going to kill it. So it completely wipes out the whole tumor. that, so because of its affinity for the cancer cell and its multiple redundant mechanisms to kill the cell, there’s none left to become drug resistant because they’re all killed the first time through. Whereas with traditional chemotherapy.

What happens there is it will kill the cells that are vulnerable, but leave the cells that aren’t. And those are known as cancer stem cells. And those are the cells that metastasize and eventually kill the patient because there’s no treatment by definition. Phenbendazole has been shown in many labs to kill those stem cells. So after they’ve developed from traditional treatment like in Christine, the taxing tax halls, you know, standard of care, chemotherapy. 

If you come in and give the animal, fan, Ben is all, kills those metastasized stem cells. So the, the, the, I have a chapter in the book. How come the people in my case reports, how did they survive after going through all the chemo? So the one thing you should realize, so I’ve got 21.

20 case reports, including my mother-in-law. And most of the people, my mother-in-law is one of the outliers who did no other treatment other than Phenbendazole. But many people, you did Phenbendazole as a last resort. They had gone through chemo, radiation, and you just can’t do that forever. You kind of reach the endpoint and the doctor says, that’s it. You know, get your affairs in order. Sorry, we did everything we could for you.

That’s when most of the people in the case reports started Fenben and lived to tell about it with no side effects. the case reports are proof positive that this works in humans. The animal research, the preclinical Petri dish research suggests that this would be a powerful anti-cancer drug.

The human case reports prove it. So do you really need to do human clinical trial and with no side effects? So it’s almost too good to be true. So I started before to tell you as a, when I was doing this book, I was 95 % sure that Fenbend is always the real deal, but being a scientist, you always have to see that there could be an uncontrolled artifact that is influencing all these successful case report, some uncontrolled variable. When, as, as a course of doing my research, when I came across this word in a published paper in 1975, on code is on code is okay. 

NCO, which means tumor dissolve. This is Fenben dissolve renamed as a cancer drug in 1976 a I knew about and Ben Dissolve as a cure for cancer. I had, here’s the paper in 1976. So they named it Octa Dissolve. So as a scientist, as a nerd, I can tell you exactly what happened. So this was done in Belgium. The scientists were experimenting with a molecule, an anti-parasitic molecule anti-parasite molecule that was off patent since 1961. 

They found that, you know, it disrupted the microtubules and rat brain tumors. And they’re just not going to do one paper. They’re going to do many things in parallel. They’re going to be testing it in animals. They’re going to give it to their friends who have cancer. They’re going to have all types of parallel experiments going. And by the time this paper comes out, they’re going to know whether they have a real cure for cancer. And they did. Two reasons. One, to name it octodissolve, tells you what its function is. When I saw that word, I knew van bendizol is a cure for cancer, and Pharma knew about it. In 1976. I go through the book and I show how I prove that it was suppressed. Would you like to know how I did that?

Dr Ron Ehrlich (36:03)

Bill, Bill, would I like to know? Yes, I would. And I’m sure my listeners would too.

William F. Supple PhD (36:10)

Okay, so and remember I said that every 20 years or so, fendendazole is rediscovered, that wheel is rediscovered, that this cures cancer. So in 2002, there was a paper, they looked at mabendazole, but again, that’s a functional equivalent for fendendazole. And this was at the University of Texas in conjunction with MD Anderson Cancer Center, which is a big cancer center here. So they did all the experiments that you would want to do to prove that mabendazole is a cure for cancer in animals.

So they showed that at very low physiological doses, it killed cancer cells, all different types of human cancer cells in the petri dish, know, breast, ovarian, prostate, lung cancer, you know, glioblastoma. So all different types of human cancers, it killed at nanomolar concentrations. Then they put it, then they implanted the tumors into rats, killed them, didn’t kill the rats, the rats were fine. So they published this paper that said, hey, we’ve discovered that this novel microtubule disruptor known as medendazole is a cure for cancer in 2002. So they mentioned, they said that it was novel three or four times. And if you go through that, references of that paper.

They don’t cite this 1976 paper because it would be unscholarly not to if they had known about it. So the 2002 paper by an Indian, his name’s hard to pronounce, but I’ll butcher it, Mercopathy, 2002 in clinical oncology. was a very high level journal that researchers didn’t know about auto-dissolve being a cure for cancer from the 1976 paper. The reviewers, the peer reviewers who were supposed to be the oncological experts didn’t know about it. And none of the readers of the paper know about it either because someone would have said, hey, wait a minute, what about that 1976 paper that found that Benzol derivative?

Is a cure for cancer. They renamed it off itself. So the paper was suppressed. So what happened? How did this paper get suppressed? Well, it’s from 1976. 1976, all journals were on paper in the stacks and medical libraries. So you had to have a physical copy of the journal. What happened in 2002? Well, that was kind of the transition from paper to digital, like the internet for science was that there were some resources, but things were still being indexed and cataloged. In 2025, when I found the paper.

Everything was digitized. You know in this paper is actually these are photographs. They’re not actually keyed in it’s a photograph of the actual paper You’ll see some of those and some of the old journals so between 2002 and 2025 a complete set of Biochemical and biophysical research communications was indexed for the internet and that’s how I found it. 

So in 2002, for the Merck Capotti paper, this paper, for whatever reason, was not available. It was suppressed. By 2025, it was available because it was somebody indexed the whole journal like they should. There was no reason not to. So I don’t know where this paper went in 2002. My guess is it’s only a four or five page paper. was probably ripped out of a lot of the journals in medical libraries. 

So if someone were to actually do the, the, the legwork, they might find that these pages are missing. So anyway, so it’s kind of like a spy novel that we have here, but the word Anka dissolve, but the word Anka dissolve kind of tells you all you need to know. They know they knew what it did.

Dr Ron Ehrlich (40:45)

And, is that article in 1976 available now? Would you, how would anyone find it?

William F. Supple PhD (40:52)

yeah. Yeah. This is the actual article. My daughter is affiliated with a university. had to have her printed out for me, but it’s, it’s available. I mean, I don’t think you can suppress it now. I actually published, actually am in the book. It’s so unbelievable. I published this page. I bought the copyright for it so that I would have a paper, a financial paper trail in case this did disappear.

So academic press, I paid them to be able to publish this in the book. So we have a financial paper trail. anyway, so it’s kind of became like this substance cures cancer. And why doesn’t my doctor know about it? Well, your doctor doesn’t know about it because he’s been duped like everyone else. It’s been suppressed.

And doctors, they knew about the power of Phenbendazole, they would certainly give it to their patients. And it doesn’t mean that it’s a binary choice. You have to choose traditional or Phenbendazole. You can do both. it’s whatever people want to do is fine. Everybody has their own life to save. 

And if you want to go a traditional route, that’s fine. If you want to go non-traditional, that’s fine, but you know, the rational thing is to go both, you know, cover your basis. And, you know, eventually what will happen, which should happen is people will say, gee, my side of my traditional treatment has all these side effects and it’s a very high risk and you know, low reward.

Dr Ron Ehrlich (42:38)

Cytotoxic?

William F. Supple PhD (42:40)

cytotoxic and you know, maybe I just want to go with the Fenban and Ivermectin and Mabendazole. So we’re kind of at a kind of a transition here where the this word tells you all you need to know. Farman knows that.

Dr Ron Ehrlich (43:02)

Let me just ask this. mean, I was going to ask you, and I think we’ve already answered this. The, what level of evidence do you think would be necessary before such an approach should be widely adopted? But, you already mentioned the terrible word that won a Nobel prize in medicine for humans, I’ve a mectin, which is another cheap, effective, safe, antiviral. 

So we’ve already had the experience and I would think any doctor listening to this would be shuddering. Well, there’s two responses. One is to say, I must try this. My patients health is at risk, is, is at stake here. And the other one would be if I tried this, I may get deregistered like a lot of doctors did who had the, the, the, the courage to use something that was effective and cheap, but not recognized by regulatory bodies.

I mean, this is a very, this is a, story is not new. Ivermectin is a good example of that, isn’t it?

William F. Supple PhD (44:07)

Yeah, well, I think what your listeners need to realize is that when doctors get cancer, they use Fendendazole. So, and I know that because they’re subscribers to my sub stack and they write in, you know, thank you for turning me on to Fendendazole. saved my life. So doctors know about it. Doctors will, it’s not standard of care. So their hands are tied.

But they will know about it after this book is out. And it’ll be up to them to push for quick clinical trials to determine the optimal dosage, the optimal co-factors that enhance absorption, and the optimal protocol. Because I think all the legwork has been done by the the basic scientists who have shown that the causal mechanism, the lack of side effects, and what the case reports have done is more or less done  clinical trials showing efficacy. Now one more thing that’s going to blow your mind. Do you have enough time to hear this?

Dr Ron Ehrlich (45:30)

Bill, Bill, Bill, please continue.

William F. Supple PhD (45:33)

Okay, so the number one question that I get on my sub stack is if this cures cancer will it prevent it? It’s kind of a chicken or egg issue, but the it’s very hard to scientifically prove a preventative agent because you you can’t prove a negative like you would never know whether you would have gotten cancer or not if you’re taking you know ground up eggshells or eating crayons or whatever it is. So it’s kind of a logical inconsistency. But what if we had a experiment in nature that was already running on a huge scale that answered that question for us? And we do. So this is what’s so exciting. I mean, I chills talking about this. This is my favorite.

Dr Ron Ehrlich (46:29)

I’m choked

listening to you and I’m guessing we’re moving towards another book

William F. Supple PhD (46:32)

No, this is in the book. So, yeah, yeah, yeah. So, again, we’re talking about anti-parasitics and we’re talking about phenbenzol, albenzol, and flubenzol. These drugs are used to control parasites on a massive scale in 123 countries around the world. There are 62 countries that don’t use them.

Dr Ron Ehrlich (46:35)

I’ll see you in book, okay?

William F. Supple PhD (47:01)

They’re the wealthier Western countries because there’s this myth that we’re clean, we don’t have parasites, and we have nothing to worry about. The developing countries administer these drugs, most notably albendazole, which is a direct analog of fendendazole, to their populations twice a year to manage parasitic infections. They have, as a group, one half the rate of cancer that the developed countries that don’t use antiparasitics do. One half. And you’re in Australia. So I’ll give you an example. So in Australia, according to the WHO, all these data are not hard to find. Anybody with an internet connection can find them. The WHO, GlobalCan, cancer incidence data. And Canada, it’s about 400 per 100,000.

You guys don’t use have mass drug administration for anti-parasite for parasite control in a place like India, which does the cancer incidence rate is 98. So it’s four times greater in Australia versus India in the U S it’s three times greater than India. Now, when you look at all the countries around the world that use antiparasitics, it’s Mexico, India, most places in Africa, you know, they’re so different genetically, culturally, diet, environment. 

The only common feature is the population wide use of antiparasitics and the fact that it’s such a dramatic effect with hap- you’re not even targeting people at risk. You’re giving it to children and adults who, who, you know, are at risk for a parasitic infection, not for cancer. Imagine if they were giving, if they were targeting older people with anti-parasitics, the rate would be. So, so the, the chapter in my book is the unexplained global disparity in cancer incidence explained. So the differential use of anti-parasitic drugs in countries that deworm the population prevents cancer. The elephant in the room is that the countries that don’t use deworm, dewormers, the rich.

Western countries have twice the incidence of cancer. They also have four times the per capita income. So the rich countries don’t use anti-parasitics and we have all types of cancer. Now you can put two and two together. You can see that where I’m going with this, that the, so what is the U S is Australia. Are we free of parasites? No.

The recently did a series of alarming articles that really got no play, but they’re in the book, basically saying that the rich, wealthy countries, including the US, are whistling through the graveyard if we think that we’re not infested with parasites. one article talks about toxoplasmosis, which you get from cats.

They estimate that in the US alone, 60 million people were chronically infected with this parasite. And that’s a lot of people. the problem with that, so the problem with being infected with, infested with a parasite is it causes inflammation.

Untreated inflammation is a major cause of cancer. we still, before when you were getting at what causes cancer, the parasite, it’s not that parasites cause cancer as a, way that most people think about it. They could as a risk factor, untreated parasitic infections could cause cancer through inflammation, through uncontrolled inflammation.

So you’re dealing with kind of like a straw that breaks the camel’s back model where you may have genetic risk factors and then you add on a uncontrolled sub-threshold untreated parasitic infection. Now you could develop cancer. that to me that’s another nail in the coffin of pharma that

Why don’t we treat in the West? Why don’t we treat for parasitic infections? Because we treat for, which affect everyone. Why do we, why are we so fanatical about vaccinations for a sporadic seasonal flu that only some people get? Yet everybody’s infected with parasites. don’t, you, you manage a parasitic infection. 

Anybody who has an animal, a pet, you know, we treat our dogs and cats periodically, maybe two, three times a year, we deworm them. Yet people kiss them on the mouth. It’s a parasitic egg transfer behavior. We get infected by the same thing. So we’re infected with parasites. We have to admit it. And all we have to do is start taking anti-parasitic drugs and we’ll prevent cancer at the same time.

Dr Ron Ehrlich (53:08)

Now, listen, listen, I mean, this, is, I mean, well, this is mind boggling. It’s, fantastic to hear this story. And it’s not a, mean, it’s taken it to a whole other level. I mean, we’ve done many stories about the influence of big farmer and big food on public health, but with millions, literally hundreds of millions of people that have died since 1976 and everybody listening to this including myself, and I’m sure you would know many people who have died. 

It’s a shocking fact. Let’s finish now. Listen, I know you’re writing another book that’s coming out in June about sunlight, and that’s a favorite topic of ours. And I think we will definitely get you back to discuss that. But I want to leave our listener now, and they’re obviously going to have to read your book.

And we’ll have links to that. But what advice would you leave our listener with who A would want to prevent and B if they had a diagnosis, what would be the protocol for taking this incredibly safe and cheap drunk?

William F. Supple PhD (54:24)

Well, what? You know, obviously I’m not a physician, so I don’t actually recommend.

William F. Supple PhD (54:37)

Right, so there’s 21 different case reports in the book and on the sub stack. There’s more case reports on the sub stack. So what I encourage people to do is go to your cancer, you know, go to your diagnosis. So if you have, you know, renal cancer, you know, non small cell lung cancer, NRAS mutated melanoma.

There’s a bunch of them there. Find ear cancer and then see what the person did. know, monkey see, monkey do. See how much they took. You know, it doesn’t mean that it’s the ideal amount to take or that what they did is what you want to do, but take a look at what they did. See what’s right for you. You know, the common theme for all the case reports is the presence or absence of Fenbendazole. 

And that doesn’t mean that down the road there’s not going to be, you know, somebody else write a book about Mbendizal or you know some other ivermectin i mean that’s going to be coming soon ivermectin has different mechanisms but just to go back to what kind of what’s happening in the background so i don’t know if you could see my book and then this book see the real Anthony Fauci here

Dr Ron Ehrlich (55:55)

Yes, yes. No, we’ll be doing a story on that.

William F. Supple PhD (55:59)

Right that’s Health and Human Services Secretary Kennedy’s book. The publisher of this book is the publisher of this book. Yep. The government knows about fennbenzo. So we’re very hopeful that things are going to happen quickly. you know, Big Pharma can make just as much money helping people live from cancer than die a slow painful death. 

So what I’m asking is that they rethink factor in something like fendendazole into their treatment models and cure people. People should live, not die. And they should, they should have, uh, uh, they should die of old age, like hopefully my mother-in-law will.

And you know, the best thing you can do once you learn about Fenbendazole and you read the book, you read the substack is when you encounter someone who has cancer to just tell them about it, let them do their own research. It’s not going to be right for everybody, but it will be right for someone. And when you help save that person, it’s a unbelievable feeling. And then

You’re motivated to go out and do it more. So there are people who have benefited from the Substack who are out there like apostles spreading the word on Phenbendazole and they’re everywhere. So it’s really a miraculous word of mouth thing. And the beauty of Phenbendazole is you can buy it on Amazon.

You know, they sell it in 50 pound bags. They dump it on cattle feed. So it’s so inexpensive. people get worried about, am I taking too much? Am I not? You just have to take some. And it would be nice to know what the ideal dose is. The minimum dose is 222 milligrams. That’s been the smallest dose. The largest dose that are in our case reports is 2000 milligrams per day. yeah, that’s kind of the range. So that’s a big range, but I have no idea, you know, what, I don’t know what the optimal dose is. From my mother-in-law, she used 222 and, you know, eradicated it so it’s, leave it to people smarter than us to figure out the ideal doses.

Well,

Dr Ron Ehrlich (58:47)

Bill, Bill, I want to, I want to thank you for, sharing this with us. It’s an extraordinary story. And, and we will of course have links to that book and to the sub stack, but thank you for sharing your journey, your knowledge and your, well, there’s not a discovery, but putting it all together and, and sharing it with us today. Thank you so much.

William F. Supple PhD (59:13)

You’re welcome. Thank you. Wow.

Dr Ron Ehrlich (59:15)

Well, I think this story highlight some of the problems in medicine. And that is that if you are a researcher and let’s face it, there are so many PhDs out there in the world now who have made their careers medical research. Well, you go looking for research money or funding to find a definitive cure for a chronic disease. One that provides a cure. Well, I think you will actually have trouble finding that money because the return on investment for whoever gives you that money is not there. 

Chronic disease management with expensive patented drugs is what the healthcare system is about. And having someone like William, who is a neuroscientist, who has done his PhD, understands scientific research, but comes at it from an open mind and free of conflict of interest. In fact, quite the opposite.

The conflict of interest for William was to find a solution to a problem. And he did that with an, has done that with an open mind. Well, is it a solution? Well, it’s certainly promising and it’s certainly empowering and it’s certainly cheap. if, if Williams research bears it out, it is also very effective. And the rationale behind it, I think is also very interesting.

So much of research now is looking at all these diseases as a metabolic disease. And I, we’ve done some programs on a ketogenic diet being way of approaching cancer because every researcher, every clinician knows that cancer loves glucose. That’s exactly what a PET scan is. You want to find out if cancer has, extended through your body. Well, you inject radioactive glucose cause research knows that cancer cells love glucose. So ketogenic diets are one way of reducing the food available to cancer cells. 

But this is a whole new way of looking at it. Now we will have links to a Williams book. Cancer is a parasite and exploring the repurposed drug, which he refers to in his in this podcast. So again, you will have links to that in the show notes. I’d encourage you to join the unstresshealth community. Until next time, this is Dr Ron Ehrlich well. 

Feeling stressed, overwhelmed? It’s time to unstress your life. Join the unstress health community and transform stress into strength. Build mental fitness from self-sabotage to self-mastery. And together, let’s not just survive, but thrive. Expert led courses, curated podcasts, like-minded community and and much more. Visit unstresshealth.com on today.

Disclaimer:

This podcast provides general information and discussion about medicine, health and related subjects. The content is not intended and should not be construed as medical advice or as a substitute for care by qualified medical practitioner. If you or any other person has a medical concern, he or she should consult with an appropriately qualified medical practitioner. Guests who speak in this podcast express their own opinions, experiences and conclusions.

Transform your health with the Unstress Health Membership